In the News

Biosimilars Council - Statement Image
July 12, 2017
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), issued this statement regarding the U.S. House of Representative’s passage of the FDA Reauthorization Act of 2017
June 11, 2017
The Association for Accessible Medicines (AAM) applauded the U.S. Supreme Court’s decision today in Sandoz Inc. v. Amgen Inc. that will help speed patient access to biosimilar versions of expensive brand-name biologic medicines.